ArticleDigestive diseases and sciences2025
Seven Hypoxia and Immune-Related Features Predict Prognosis in Patients with Hepatocellular Carcinoma.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe role of hypoxia and immunity in the progression of hepatocellular carcinoma (HCC) was highly critical. However, there were few application-based studies on hypoxia and immune molecules in HCC prognosis prediction. This study aims to reveal the prognostic significance of hypoxia- and immune-related genes in HCC.
methodsWe identified the hypoxia- and immune-related differentially expressed genes (HIDEGs) from the Cancer Genome Atlas (TCGA). Seven HIDEGs associated with the prognosis of HCC were identified with the Cox regression and LASSO analysis. The prognosis model was validated in both the TCGA (n = 420) and Gene Expression Omnibus (GEO) (GSE14520-GPL3921, n = 222) databases. CIBERSORT was applied to measure the fractions of immune cell types. The drug sensitivity analysis was used to evaluate the applicability of drug treatment to HCC patients. The effect of ADM on the malignant biological behaviors of HCC was measured by plate colony formation assay, Cell Counting Kit-8 (CCK-8) assay, scratch wound assay and Transwell migration and invasion assays.
resultsWe identified 78 HIRDEGs associated with survival time in HCC, among them, seven genes were chosen to construct a prognosis model. The prognosis model showed good performance in predicting prognosis in HCC patients in both the TCGA (n = 420) and Gene Expression Omnibus (GEO) (GSE14520-GPL3921, n = 222) databases. Based on the median risk score, HCC patients were classified into high- and low-risk groups. The high-risk group suffered worse survival time and contained higher proportions of M0/M1 macrophages and monocytes, and showed greater expression of classical immune checkpoints, including PD-1, PD-L1, and CTLA4. Furthermore, we presented that ADM was up-regulated by hypoxia, and silencing its expression suppressed HCC cells proliferation, migration, and invasion in vitro.
conclusionThe hypoxia- and immune-related signatures are promising biomarkers for HCC prognosis. ADM might be a novel target for HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.